Geron Corporation Announces Presentation Of New Data Supporting The Utility Of Its Small Molecule Telomerase Activator Drugs For HIV/AIDS Therapy

MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 3, 2006--Geron Corporation (Nasdaq:GERN) announced today the presentation of studies showing that its small molecule telomerase activators, TAT0001 and TAT0002, enhance the functional activity of immune cells from HIV/AIDS donors. The research, presented at the Gordon Research Conference "The Biology of Aging" in Ventura, California, demonstrated that the telomerase activators not only increased the proliferative capacity of cytotoxic (CD8+) T-cells and their ability to produce a virus-fighting molecule, gamma Interferon (IFN(gamma)), but also improved the ability of CD8+ cells from HIV-positive donors to inhibit virus production in infected CD4+ T-cells.

Back to news